There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ascendis Pharma (ASND – Research Report) and BioRestorative Therapies (BRTX – Research Report) with bullish sentiments.
Ascendis Pharma (ASND)
Goldman Sachs analyst Paul Choi maintained a Buy rating on Ascendis Pharma today. The company’s shares closed last Wednesday at $88.15.
According to TipRanks.com, Choi is a 4-star analyst with an average return of
Ascendis Pharma has an analyst consensus of Strong Buy, with a price target consensus of $139.00, which is a 61.6% upside from current levels. In a report issued on June 20, Wedbush also reiterated a Buy rating on the stock with a $187.00 price target.
See today’s best-performing stocks on TipRanks >>
BioRestorative Therapies (BRTX)
Maxim Group analyst Michael Okunewitch maintained a Buy rating on BioRestorative Therapies yesterday. The company’s shares closed last Wednesday at $4.91.
According to TipRanks.com, Okunewitch ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The the analyst consensus on BioRestorative Therapies is currently a Moderate Buy rating.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ASND:
- Ascendis Pharma presents one-year data from Phase 3 trial of TransCon PTH
- One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented at ENDO 2023
- Ascendis Pharma assumed with a Neutral at Credit Suisse
- Ascendis Pharma Showcases Its Latest Endocrinology Programs, Data, and Research at ENDO 2023
- Ascendis Pharma to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
